Complications

A risk for falls is best addressed by assessments by a physical therapist.

If questions or concerns arise regarding the patient's job performance, an evaluation of his or her functional or physical capacity may be appropriate. A physical therapist or staff at a rehabilitation center typically performs this evaluation. Patients are understandably reluctant to surrender their functional independence. However, they must not be a danger to themselves or others while working or performing their activities of daily living.

If the patient's ability to operate a motor vehicle is a concern, this concern should be noted in the chart, and the patient should be advised to seek further evaluation by means of formal assessment at a rehabilitation center or the local Department of Motor Vehicles or its equivalent.

Prognosis

As stated, the life expectancy is not reported to be reduced in Kennedy disease if care has been taken to prevent complications (eg, aspiration, falls).

Patient Education

See the list below:

The treating physician must have an ongoing dialogue with the patient to keep him or her informed about the status of the disease.
Although patient issues should be addressed as needed, the physician must be proactive and anticipate issues such as potential difficulties with driving and other activities of daily living.
The treating physician should maintain a balance between the reality of the patient's disease process and a sense of hope and the patient's ability to cope with the disease.
National Organization for Rare Disorders: This association addresses some uncommon or orphan neurologic disorders for which no dedicated organization exists.
Kennedy's Disease Association

Questions

Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology. 1968 Jul. 18(7):671-80. [QxMD MEDLINE Link].
Schoenen J, Delwaide PJ, Legros JJ, Franchimont P. Hereditary motor neuron disease: the proximal, adult, sex-linked form (or Kennedy disease): clinical and neuroendocrinologic observations in French]. J Neurol Sci. 1979 May. 41(3):343-57. [QxMD MEDLINE Link].
Harding AE, Thomas PK, Baraitser M, et al. X-linked recessive bulbospinal neuronopathy: a report of ten cases. J Neurol Neurosurg Psychiatry. 1982 Nov. 45(11):1012-9. [QxMD MEDLINE Link].
Arbizu T, Santamaria J, Gomez JM, et al. A family with adult spinal and bulbar muscular atrophy, X-linked inheritance and associated testicular failure. J Neurol Sci. 1983 Jun. 59(3):371-82. [QxMD MEDLINE Link].
Fischbeck KH, Ionasescu V, Ritter AW, et al. Localization of the gene for X-linked spinal muscular atrophy. Neurology. 1986 Dec. 36(12):1595-8. [QxMD MEDLINE Link].
La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991 Jul 4. 352(6330):77-9. [QxMD MEDLINE Link].
Cooper DN, Krawczak M, Antonarakis SE. The nature and mechanisms of human gene mutation. Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995. 281.
La Spada AR. Spinal and bulbar muscular atrophy. Gene Reviews. Gene Tests. Available at http://www.geneclinics.org. Accessed: October 19, 2000.
Sobue G, Hashizume Y, Mukai E, et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain. 1989 Feb. 112 ( Pt 1):209-32. [QxMD MEDLINE Link].
Terao S, Sobue G, Hashizume Y, et al. Disease-specific patterns of neuronal loss in the spinal ventral horn in amyotrophic lateral sclerosis, multiple system atrophy and X-linked recessive bulbospinal neuronopathy, with special reference to the loss of small neurons in the intermediate zone. J Neurol. 1994 Feb. 241(4):196-203. [QxMD MEDLINE Link].
Li M, Sobue G, Doyu M, et al. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression. Muscle Nerve. 1995 Mar. 18(3):301-8. [QxMD MEDLINE Link].
Thurtell MJ, Pioro EP, Leigh RJ. Abnormal eye movements in Kennedy disease. Neurology. 2009 Apr 28. 72(17):1528-30. [QxMD MEDLINE Link]. [Full Text].
Rocchi C, Greco V, Urbani A, Di Giorgio A, Priori M, Massa R. Subclinical autonomic dysfunction in spinobulbar muscular atrophy (Kennedy disease). Muscle Nerve. 2011 Nov. 44(5):737-40. [QxMD MEDLINE Link].
Vucic S, Kiernan MC. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol. 2008 May. 119(5):1088-96. [QxMD MEDLINE Link].
Li M, Miwa S, Kobayashi Y, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol. 1998 Aug. 44(2):249-54. [QxMD MEDLINE Link].
Walcott JL, Merry DE. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J Biol Chem. 2002 Dec 27. 277(52):50855-9. [QxMD MEDLINE Link].
Echaniz-Laguna A, Rousso E, Anheim M, Cossée M, Tranchant C. A family with early-onset and rapidly progressive X-linked spinal and bulbar muscular atrophy. Neurology. 2005 Apr 26. 64(8):1458-60. [QxMD MEDLINE Link].
Lieberman AP, Harmison G, Strand AD, et al. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet. 2002 Aug 15. 11(17):1967-76. [QxMD MEDLINE Link].
Cary GA, La Spada AR. Androgen receptor function in motor neuron survival and degeneration. Phys Med Rehabil Clin N Am. 2008. 19(3):479-91.
Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005 Oct. 6(10):743-55. [QxMD MEDLINE Link].
Adachi H, Waza M, Katsuno M, Tanaka F, Doyu M, Sobue G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol Appl Neurobiol. 2007 Apr. 33(2):135-51. [QxMD MEDLINE Link].
Palazzolo I, Gliozzi A, Rusmini P, Sau D, Crippa V, Simonini F. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol. 2008 Feb. 108(3-5):245-53. [QxMD MEDLINE Link].
Beitel LK, Alvarado C, Mokhtar S, Palouras M, Trifiro M. Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction. Frontiers of Neurology. 2013. 4(53):1-16.
Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007 Jun 14. 447 (7146):859-63. [QxMD MEDLINE Link].
Grunseich C, Zukosky K, Kats IR, Ghosh L, Harmison GG, Bott LC, et al. Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients. Neurobiol Dis. 2014 Oct. 70:12-20. [QxMD MEDLINE Link].
Sobue G, Doyu M, Kachi T, et al. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci. 1993 Jul. 117(1-2):74-8. [QxMD MEDLINE Link].
Greenland KJ, Beilin J, Castro J, Varghese PN, Zajac JD. Polymorphic CAG repeat length in the androgen receptor gene and association with neurodegeneration in a heterozygous female carrier of Kennedy's disease. J Neurol. 2004 Jan. 251(1):35-41. [QxMD MEDLINE Link].
Amato AA, Prior TW, Barohn RJ, Snyder P, Papp A, Mendell JR. Kennedy's disease: a clinicopathologic correlation with mutations in the androgen receptor gene. Neurology. 1993 Apr. 43(4):791-4. [QxMD MEDLINE Link].
Sinnreich M, Sorenson EJ, Klein CJ. Neurologic course, endocrine dysfunction and triplet repeat size in spinal bulbar muscular atrophy. Can J Neurol Sci. 2004 Aug. 31(3):378-82. [QxMD MEDLINE Link].
Doyu M, Sobue G, Mukai E, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol. 1992 Nov. 32(5):707-10. [QxMD MEDLINE Link].
Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab. 2002 Aug. 87(8):3893-901. [QxMD MEDLINE Link].
Van Golde R, Van Houwelingen K, Kiemeney L, et al. Is increased CAG repeat length in the androgen receptor gene a risk factor for male subfertility?. J Urol. 2002 Feb. 167(2 Pt 1):621-3. [QxMD MEDLINE Link].
Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol. 2001 Jun 20. 179(1-2):105-9. [QxMD MEDLINE Link].
LaFevre-Bernt MA, Ellerby LM. Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J Biol Chem. 2003 Sep 12. 278(37):34918-24. [QxMD MEDLINE Link].
Lee DK, Chang C. Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab. 2003 Sep. 88(9):4043-54. [QxMD MEDLINE Link].
Matsumoto T, Takeyama K, Sato T, Kato S. Androgen receptor functions from reverse genetic models. J Steroid Biochem Mol Biol. 2003 Jun. 85(2-5):95-9. [QxMD MEDLINE Link].
Cullen DA, Killick R, Leigh PN, Gallo JM. The effect of polyglutamine expansion in the human androgen receptor on its ability to suppress beta-catenin-Tcf/Lef dependent transcription. Neurosci Lett. 2004 Jan 2. 354(1):54-8. [QxMD MEDLINE Link].
Kato S, Matsumoto T, Kawano H, et al. Function of androgen receptor in gene regulations. J Steroid Biochem Mol Biol. 2004 May. 89-90(1-5):627-33. [QxMD MEDLINE Link].
Thomas M, Dadgar N, Aphale A, et al. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J Biol Chem. 2004 Feb 27. 279(9):8389-95. [QxMD MEDLINE Link].
Ellerby LM, Hackam AS, Propp SS, Ellerby HM, Rabizadeh S, Cashman NR. Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem. 1999 Jan. 72(1):185-95. [QxMD MEDLINE Link].
Greenland KJ, Zajac JD. Kennedy's disease: pathogenesis and clinical approaches. Intern Med J. 2004 May. 34(5):279-86. [QxMD MEDLINE Link].
Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, Fischbeck KH. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet. 2009 Jan 1. 18(1):27-42. [QxMD MEDLINE Link]. [Full Text].
Parboosingh JS, Figlewicz DA, Krizus A, Meininger V, Azad NA, Newman DS. Spinobulbar muscular atrophy can mimic ALS: the importance of genetic testing in male patients with atypical ALS. Neurology. 1997 Aug. 49(2):568-72. [QxMD MEDLINE Link].
Sperfeld AD, Karitzky J, Brummer D, Schreiber H, Häussler J, Ludolph AC. X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol. 2002 Dec. 59(12):1921-6. [QxMD MEDLINE Link].
Udd B, Juvonen V, Hakamies L, Nieminen A, Wallgren-Pettersson C, Cederquist K. High prevalence of Kennedy's disease in Western Finland -- is the syndrome underdiagnosed?. Acta Neurol Scand. 1998 Aug. 98(2):128-33. [QxMD MEDLINE Link].
Tanaka F, Doyu M, Ito Y, et al. Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum Mol Genet. 1996 Sep. 5(9):1253-7. [QxMD MEDLINE Link].
Dobyns WB, Filauro A, Tomson BA, et al. Inheritence of Most X-linked traits Is Not Dominant or Recessive, Just X-linked. Am J Med Gen. 2004. 129:136-143.
Doyu M, Sobue G, Mitsuma T, et al. Very late onset X-linked recessive bulbospinal neuronopathy: mild clinical features and a mild increase in the size of tandem CAG repeat in androgen receptor gene. J Neurol Neurosurg Psychiatry. 1993 Jul. 56(7):832-3. [QxMD MEDLINE Link].
Battaglia F, Le Galudec V, Cossee M, Tranchant C, Warter JM, Echaniz-Laguna A. Kennedy's Disease Initially Manifesting as an Endocrine Disorder. J Clin Neuromuscul Dis. 2003 Jun. 4(4):165-167. [QxMD MEDLINE Link].
Sumner CJ, Fischbeck KH. Jaw drop in Kennedy's disease. Neurology. 2002 Nov 12. 59(9):1471-2. [QxMD MEDLINE Link].
Sperfeld AD, Hanemann CO, Ludolph AC, Kassubek J. Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology. 2005 Feb 22. 64(4):753-4. [QxMD MEDLINE Link].
Ferrante MA, Wilbourn AJ. The characteristic electrodiagnostic features of Kennedy's disease. Muscle Nerve. 1997 Mar. 20(3):323-9. [QxMD MEDLINE Link].
Pachatz C, Terracciano C, Desiato MT, Orlacchio A, Mori F, Rocchi C. Upper motor neuron involvement in X-linked recessive bulbospinal muscular atrophy. Clin Neurophysiol. 2007 Feb. 118(2):262-8. [QxMD MEDLINE Link].
Antonini G, Gragnani F, Romaniello A, Pennisi EM, Morino S, Ceschin V. Sensory involvement in spinal-bulbar muscular atrophy (Kennedy's disease). Muscle Nerve. 2000 Feb. 23(2):252-8. [QxMD MEDLINE Link].
Polo A, Teatini F, D'Anna S, Manganotti P, Salviati A, Dallapiccola B. Sensory involvement in X-linked spino-bulbar muscular atrophy (Kennedy's syndrome): an electrophysiological study. J Neurol. 1996 May. 243(5):388-92. [QxMD MEDLINE Link].
Manganelli F, Iodice V, Provitera V, Pisciotta C, Nolano M, Perretti A. Small-fiber involvement in spinobulbar muscular atrophy (Kennedy's disease). Muscle Nerve. 2007 Dec. 36(6):816-20. [QxMD MEDLINE Link].
Sinclair R, Greenland KJ, Egmond S, Hoedemaker C, Chapman A, Zajac JD. Men with Kennedy disease have a reduced risk of androgenetic alopecia. Br J Dermatol. 2007 Aug. 157(2):290-4. [QxMD MEDLINE Link].
Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994 Jul. 124 Suppl:96-107. [QxMD MEDLINE Link].
Bauer M, Bergstrom R, Ritter B, et al. Macroglobulinemia Waldenstrom and motor neuron syndrome. Acta neurol Scand. 1977. 55:245-250.
Isoardo G, Troni W. Sporadic bulbospinal muscle atrophy with facial-onset sensory neuropathy. Muscle Nerve. 2008 May. 37(5):659-62. [QxMD MEDLINE Link].
Vucic S, Tian D, Chong PS, Cudkowicz ME, Hedley-Whyte ET, Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain. 2006 Dec. 129:3384-90. [QxMD MEDLINE Link].
Trentin A, Scola R, Teive H, et al. Kennedy's disease phenotype with positive genetic study for Kugelberg-Welander's disease: case report. Muscle Nerve. 2003. (Suppl 12):S55.
Krishnan AV, Pamphlett R, Burke D, et al. Cytoplasmic body myopathy masquerading as motor neuron disease. Muscle Nerve. 2004 Nov. 30(5):667-72. [QxMD MEDLINE Link].
Albers JW, Bromberg MB. X-linked bulbospinomuscular atrophy (Kennedy's disease) masquerading as lead neuropathy. Muscle Nerve. 1994 Apr. 17(4):419-23. [QxMD MEDLINE Link].
Thomas PK, Young E, King RH. Sandhoff disease mimicking adult-onset bulbospinal neuronopathy. J Neurol Neurosurg Psychiatry. 1989 Sep. 52(9):1103-6. [QxMD MEDLINE Link].
Wang Z, Thibodeau SN. A polymerase chain reaction-based test for spinal and bulbar muscular atrophy. Mayo Clin Proc. 1996 Apr. 71(4):397-8. [QxMD MEDLINE Link].
Barkhaus PE, Kennedy WR, Stern LZ, Harrington RB. Hereditary proximal spinal and bulbar motor neuron disease of late onset. A report of six cases. Arch Neurol. 1982 Feb. 39(2):112-6. [QxMD MEDLINE Link].
Sorenson EJ, Klein CJ. Elevated creatine kinase and transaminases in asymptomatic SBMA. Amyotroph Lateral Scler. 2007 Feb. 8(1):62-4. [QxMD MEDLINE Link].
Hamano T, Mutoh T, Hirayama M, Kawamura Y, Nagata M, Fujiyama J. Muscle MRI findings of X-linked spinal and bulbar muscular atrophy. J Neurol Sci. 2004 Jul 15. 222(1-2):93-7. [QxMD MEDLINE Link].
Olney RK, Aminoff MJ, So YT. Clinical and electrodiagnostic features of X-linked recessive bulbospinal neuronopathy. Neurology. 1991 Jun. 41(6):823-8. [QxMD MEDLINE Link].
Meriggioli MN, Rowin J. Fatigue and abnormal neuromuscular transmission in Kennedy's disease. Muscle Nerve. 2003 Feb. 27(2):249-51. [QxMD MEDLINE Link].
Warnecke T, Oelenberg S, Teismann I, Suntrup S, Hamacher C, Young P. Dysphagia in X-linked bulbospinal muscular atrophy (Kennedy disease). Neuromuscul Disord. 2009 Oct. 19(10):704-8. [QxMD MEDLINE Link].
Mano T, Katsuno M, Banno H, Suzuki K, Suga N, Hashizume A, et al. Tongue pressure as a novel biomarker of spinal and bulbar muscular atrophy. Neurology. 2014 Jan 21. 82 (3):255-62. [QxMD MEDLINE Link].
Sorarù G, D'Ascenzo C, Polo A, Palmieri A, Baggio L, Vergani L, et al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci. 2008 Jan 15. 264(1-2):100-5. [QxMD MEDLINE Link].
Goldenberg JN, Bradley WG. Testosterone therapy and the pathogenesis of Kennedy's disease (X-linked bulbospinal muscular atrophy). J Neurol Sci. 1996 Feb. 135(2):158-61. [QxMD MEDLINE Link].
Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol. 2009 Feb. 65(2):140-50. [QxMD MEDLINE Link].
Fischbeck KH, Bryan WW. Anti-androgen treatment for spinal and bulbar muscular atrophy. Ann Neurol. 2009 Feb. 65(2):119-20. [QxMD MEDLINE Link].
Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Sep. 9(9):875-84. [QxMD MEDLINE Link].
Fernández-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb. 10(2):140-7. [QxMD MEDLINE Link].
Fischbeck KH. A role for androgen reduction treatment in Kennedy disease?. Muscle Nerve. 2013 Jun. 47 (6):789. [QxMD MEDLINE Link].
Rocchi A, Pennuto M. New Routes to Therapy for Spinal and Bulbar Muscular Atrophy. J Mol Neurosci. 2013. 50:514-523.
Querin G, D’Ascenza C, Peterle E, et al. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology. 2013. 80:2095-2099.
Okamoto E, Nitahara K, Yasumoto M, Higa K. Use of epidural anaesthesia for surgery in a patient with Kennedy's disease. Br J Anaesth. 2004 Mar. 92(3):432-3. [QxMD MEDLINE Link].
Preisler N, Andersen G, Thøgersen F, Crone C, Jeppesen TD, Wibrand F, et al. Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurology. 2009 Jan 27. 72(4):317-23. [QxMD MEDLINE Link].
Shrader JA, Kats I, Kokkinis A, Zampieri C, Levy E, Joe GO, et al. A randomized controlled trial of exercise in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol. 2015 Jul. 2 (7):739-47. [QxMD MEDLINE Link].
Mano T, Katsuno M, Banno H, Suzuki K, Suga N, Hashizume A, et al. Head Lift Exercise Improves Swallowing Dysfunction in Spinal and Bulbar Muscular Atrophy. Eur Neurol. 2015. 74 (5-6):251-8. [QxMD MEDLINE Link].
Sumner C, Fishbeck KH. Kennedy's disease. Shaw PJ, Strong MJ, eds. Motor Neuron Disorders. Philadelphia, PA: Butterworth-Heineman; 2003. 425-34.

Media Gallery

Note wasting in the thighs and shoulders. The arms hang down and are rotated internally so that the thumbs point toward the patient (ie, simian posture) rather than forward, as in a healthy individual. This observation strongly suggests weakness in shoulder girdle muscles.
Prominence of breast tissue consistent with gynecomastia in Kennedy disease.
The forehead of this patient with Kennedy disease is smooth, in fact, too smooth for a man this age. The smoothness is particularly noticeable when the patient tries to perform upgaze, when wrinkling of the forehead due to contraction of the frontalis is expected.
Photographs show asymmetry at rest due to facial weakness, which is enhanced when the muscles are activated by pursing the lips.
Note the scalloping of the borders of the tongue, which strongly suggests wasting. In addition, the marked wasting of the large group of glossal muscles on each side has caused them to separate and form a midline furrow.
Motor-unit action potentials recorded from the biceps brachii in a patient with Kennedy disease. Upper tracing shows 2 action potentials discharging during low-to-moderate effort. In a healthy person, additional discharges are expected. (Calibration is 1 mV per division on the vertical axis and 10 ms per division on the horizontal axis.) Potential on the left is approximately 1.2 mV and 26 ms. It is moderately increased in amplitude, almost twice the upper limit in duration, and shows marked irregularity or serrations (ie, turns) in the main component. Potential to the right is markedly increased in amplitude (approximately 3.3 mV), and its duration is at least 30 ms but cannot be measured on this tracing because it extends off to the right and qualifies as a giant motor-unit action potential. Bottom tracing shows the same 2 potentials at standard setting used to view motor-unit action potentials (0.1 mV per vertical division), which emphasizes their large size and complexity (ie, increased number of changes in polarity of the waveform).
Recording of motor-unit action potentials from the pectoralis muscle in a patient with Kennedy disease. Calibration is 1 mV per division on the vertical axis and 10 ms per division on the horizontal axis. The patient's level of effort in activation is high. Therefore, the number of motor unit action potentials clearly is reduced, and the individual potentials observed are enlarged, consistent with a chronic neurogenic process.

of 7

Table 1. Primary Differential Diagnoses of Kennedy Disease

Disease	Differentiating Characteristics or Tests
ALS	Upper motor neuron involvement with tendency for distal-greater-than-proximal weakness^[58]
Spinal muscular atrophy	See Table 2 below
Fascioscapulohumeral muscular dystrophy	Autosomal dominant pattern with myopathic findings on muscle biopsy and EMG, positive genetic marker
Myasthenia gravis - Adult acquired form	Extraocular muscle frequently involved, EMG consistent with neuromuscular transmission disorder, acetylcholine receptor antibodies frequently positive
Oculopharyngeal muscular dystrophy	Autosomal dominant pattern, late onset, predominant involvement of bulbar muscle with ptosis and mild ophthalmoparesis, EMG and muscle biopsy results consistent with myopathic process, positive genetic marker
Hexosaminidase A deficiency	Rectal biopsy, enzyme assay
Sandhoff disease	Rectal biopsy, enzyme assay
Syphilis (neurovascular form)	Positive serology
Lead neuropathy	Index of suspicion based on potential exposure; anemia; elevated serum, blood, and urine lead levels
Motor neuron disease with macroglobulinemia	Monoclonal gammopathy^[59]
Autosomal dominant cerebellar ataxia type I	Amyotrophy occasionally prominent finding in SCAs, particularly types II and III; other clinical and laboratory findings suggest condition other than a pure motor-neuron process; appropriate tests of genetic markers for SCA
Polymyositis	Elevated serum creatine kinase, EMG and muscle-biopsy results consistent with inflammatory myopathy
Cervical spondylosis	Rostral cervical segmental myotomes (eg, C5, C6) commonly affected, but pattern on EMG testing is highly localizing; possible pyramidal-tract signs if spondylosis compresses spinal cord at same segmental level; no evidence of lower motor-neuro involvement in legs; imaging (eg, cervical MRI, myelography with low-dose CT) findings correlated with suspected lesion
Facial onset sensory and motor neuropathy (FOSMN syndrome)^{[60, 61]}	Slow progressing, trigeminal-onset sensory loss that may spread to upper limbs and torso, associated with lower motor syndrome with prominent bulbar involvement

Table 2. Patterns of Hereditary Spinal Muscular Atrophies that May Resemble Kennedy Disease

Pattern	Characteristics*
Bulbar hereditary motor neuropathy affecting lowest 6 cranial nerves (Fazio-Londe disease)	Autosomal recessive, onset in childhood, limbs not affected; when associated with deafness, pattern called Vialleto-van Laere disease, which may be X-linked or autosomal dominant
Scapuloperoneal hereditary motor neuropathy	Variable transmission: dominant, recessive, X-linked; pattern of weakness as described; bulbar muscles spared
Fascioscapulohumeral hereditary motor neuropathy	Autosomal dominant, pattern of weakness as described
Hereditary motor neuronopathy with oculopharyngeal involvement	Described in Japanese individuals; autosomal recessive or dominant; ophthalmoplegia, dysarthria, and dysphagia
Hereditary proximal motor neuropathy	Variable dominant or recessive inheritance; onset usually in first 2 decades; bulbar muscles spared
Hereditary distal motor neuropathy	Usually recessive inheritance; onset usually in first 2 decades; bulbar muscles spared; autosomal-dominant distal spinal muscular atrophy linked to chromosome 7 (same locus as that of hereditary sensorimotor neuropathy type 2D)^[62]
*In none of these diseases are results of test for the KD marker positive, and associated endocrinopathy or sensory nerve conduction abnormality should be absent.

Back to List

Author

David A Shirilla, DO Neuromuscular Medicine Fellow, University of Kansas Medical Center

David A Shirilla, DO is a member of the following medical societies: American Academy of Neurology, American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Paul E Barkhaus, MD, FAAN, FAANEM Professor of Neurology and Physical Medicine and Rehabilitation, Chief, Neuromuscular and Autonomic Disorders Program, Director, ALS Program, Department of Neurology, Medical College of Wisconsin

Paul E Barkhaus, MD, FAAN, FAANEM is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Clinical Neurophysiology Society, American Neurological Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Neil A Busis, MD Chief of Neurology and Director of Neurodiagnostic Laboratory, UPMC Shadyside; Clinical Professor of Neurology and Director of Community Neurology, Department of Neurology, University of Pittsburgh Physicians

Neil A Busis, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Academy of Neurology<br/>Serve(d) as a speaker or a member of a speakers bureau for: American Academy of Neurology<br/>Received income in an amount equal to or greater than $250 from: American Academy of Neurology.

Chief Editor

Nicholas Lorenzo, MD, CPE, MHCM, FAAPL Co-Founder and Former Chief Publishing Officer, eMedicine and eMedicine Health, Founding Editor-in-Chief, eMedicine Neurology; Founder and Former Chairman and CEO, Pearlsreview; Founder and CEO/CMO, PHLT Consultants; Former Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, CPE, MHCM, FAAPL is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association for Physician Leadership

Disclosure: Nothing to disclose.

Additional Contributors

Rodrigo O Kuljis, MD Esther Lichtenstein Professor of Psychiatry and Neurology, Director, Division of Cognitive and Behavioral Neurology, Department of Neurology, University of Miami School of Medicine

Rodrigo O Kuljis, MD is a member of the following medical societies: American Academy of Neurology, Society for Neuroscience

Disclosure: Nothing to disclose.

Sumit Verma, MD Assistant Professor of Pediatrics, Assistant Professor of Neurology, Emory University School of Medicine; Pediatric Neurologist, Medical Director, Neuromuscular Program, Director, EMG Laboratory, Director, MDA Clinic Care Center, Children’s Healthcare of Atlanta

Sumit Verma, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Child Neurology Society, Indian Academy of Pediatrics

Disclosure: Nothing to disclose.

Acknowledgements

The author acknowledges support in part from the Department of Veterans Affairs.

Disclaimer: This article does not necessarily reflect the views of the Department of Veterans Affairs or the United States Government.